These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 18826953)

  • 1. Identifying key components of the PrPC-PrPSc replicative interface.
    Abalos GC; Cruite JT; Bellon A; Hemmers S; Akagi J; Mastrianni JA; Williamson RA; Solforosi L
    J Biol Chem; 2008 Dec; 283(49):34021-8. PubMed ID: 18826953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mouse prion protein (PrP) segment 100 to 104 regulates conversion of PrP(C) to PrP(Sc) in prion-infected neuroblastoma cells.
    Hara H; Okemoto-Nakamura Y; Shinkai-Ouchi F; Hanada K; Yamakawa Y; Hagiwara K
    J Virol; 2012 May; 86(10):5626-36. PubMed ID: 22398286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The charge structure of helix 1 in the prion protein regulates conversion to pathogenic PrPSc.
    Norstrom EM; Mastrianni JA
    J Virol; 2006 Sep; 80(17):8521-9. PubMed ID: 16912302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward molecular dissection of PrPC-PrPSc interactions.
    Solforosi L; Bellon A; Schaller M; Cruite JT; Abalos GC; Williamson RA
    J Biol Chem; 2007 Mar; 282(10):7465-71. PubMed ID: 17218310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prion protein self-peptides modulate prion interactions and conversion.
    Rigter A; Priem J; Timmers-Parohi D; Langeveld JP; van Zijderveld FG; Bossers A
    BMC Biochem; 2009 Nov; 10():29. PubMed ID: 19943977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disulfide-crosslink scanning reveals prion-induced conformational changes and prion strain-specific structures of the pathological prion protein PrP
    Taguchi Y; Lu L; Marrero-Winkens C; Otaki H; Nishida N; Schatzl HM
    J Biol Chem; 2018 Aug; 293(33):12730-12740. PubMed ID: 29934306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc.
    Moroncini G; Kanu N; Solforosi L; Abalos G; Telling GC; Head M; Ironside J; Brockes JP; Burton DR; Williamson RA
    Proc Natl Acad Sci U S A; 2004 Jul; 101(28):10404-9. PubMed ID: 15240877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of RNAi-mediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations.
    Kim Y; Han B; Titlow W; Mays CE; Kwon M; Ryou C
    Antiviral Res; 2009 Nov; 84(2):185-93. PubMed ID: 19748523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virus Infection, Genetic Mutations, and Prion Infection in Prion Protein Conversion.
    Hara H; Sakaguchi S
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying critical sites of PrP(c)-PrP(Sc) interaction in prion-infected cells by dominant-negative inhibition.
    Taguchi Y; Schätzl HM
    Prion; 2013; 7(6):452-6. PubMed ID: 24401595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological mimicry of PrPC-PrPSc interactions: antibody-induced PrP misfolding.
    Li L; Guest W; Huang A; Plotkin SS; Cashman NR
    Protein Eng Des Sel; 2009 Aug; 22(8):523-9. PubMed ID: 19602568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The octarepeat region of the prion protein is conformationally altered in PrP(Sc).
    Yam AY; Gao CM; Wang X; Wu P; Peretz D
    PLoS One; 2010 Feb; 5(2):e9316. PubMed ID: 20195363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discriminating between cellular and misfolded prion protein by using affinity to 9-aminoacridine compounds.
    Phuan PW; Zorn JA; Safar J; Giles K; Prusiner SB; Cohen FE; May BCH
    J Gen Virol; 2007 Apr; 88(Pt 4):1392-1401. PubMed ID: 17374787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of rafts in the fibrillization and aggregation of prions.
    Pinheiro TJ
    Chem Phys Lipids; 2006 Jun; 141(1-2):66-71. PubMed ID: 16647049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of monoclonal antibody that distinguishes PrPSc from PrPC and neutralizes prion infectivity.
    Horiuchi M; Karino A; Furuoka H; Ishiguro N; Kimura K; Shinagawa M
    Virology; 2009 Nov; 394(2):200-7. PubMed ID: 19766283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant prion protein refolded with lipid and RNA has the biochemical hallmarks of a prion but lacks in vivo infectivity.
    Timmes AG; Moore RA; Fischer ER; Priola SA
    PLoS One; 2013; 8(7):e71081. PubMed ID: 23936256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The AGAAAAGA palindrome in PrP is required to generate a productive PrPSc-PrPC complex that leads to prion propagation.
    Norstrom EM; Mastrianni JA
    J Biol Chem; 2005 Jul; 280(29):27236-43. PubMed ID: 15917252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sialylation of prion protein controls the rate of prion amplification, the cross-species barrier, the ratio of PrPSc glycoform and prion infectivity.
    Katorcha E; Makarava N; Savtchenko R; D'Azzo A; Baskakov IV
    PLoS Pathog; 2014 Sep; 10(9):e1004366. PubMed ID: 25211026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of genuine prion infectivity by serial PMCA.
    Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
    Vet Microbiol; 2007 Aug; 123(4):346-57. PubMed ID: 17493773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human prion protein inhibits prion propagation in vitro.
    Yuan J; Zhan YA; Abskharon R; Xiao X; Martinez MC; Zhou X; Kneale G; Mikol J; Lehmann S; Surewicz WK; Castilla J; Steyaert J; Zhang S; Kong Q; Petersen RB; Wohlkonig A; Zou WQ
    Sci Rep; 2013 Oct; 3():2911. PubMed ID: 24105336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.